By Professor Yong Li

Journal articles

You J; Willcox M; Fitzgerald A; Schiller B; Cozzi PJ; Russell PJ; Walsh BJ; Wasinger VC; Graham PH; Li Y, 2016, 'Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling', Analytical Biochemistry, 496, pp. 30 - 34, http://dx.doi.org/10.1016/j.ab.2015.12.006

Chang L; Graham P; Hao J; Ni J; Deng J; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Cancer stem cells and signaling pathways in radioresistance', Oncotarget, 7, pp. 11002 - 11017, http://dx.doi.org/10.18632/oncotarget.6760

Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy', Oncotarget, 7, pp. 74269 - 74285, http://dx.doi.org/10.18632/oncotarget.12368

Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y, 2016, 'Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer', Oncotarget, 7, pp. 55771 - 55788, http://dx.doi.org/10.18632/oncotarget.9908

Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y, 2016, 'Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer', Oncotarget, 7, pp. 55518 - 55528, http://dx.doi.org/10.18632/oncotarget.10833

Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y, 2015, 'Proteomics discovery of radioresistant cancer biomarkers for radiotherapy', Cancer Letters, 369, pp. 289 - 297, http://dx.doi.org/10.1016/j.canlet.2015.09.013

Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y, 2015, 'Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance', Critical Reviews in Oncology/Hematology, 96, pp. 507 - 517, http://dx.doi.org/10.1016/j.critrevonc.2015.07.005

Beretov J; Wasinger VC; Millar EKA; Schwartz P; Graham PH; Li Y, 2015, 'Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach', PLoS ONE, 10, pp. e0141876, http://dx.doi.org/10.1371/journal.pone.0141876

Dong Y; Huang J; Li G; Li L; Li W; Li X; Liu X; Liu Z; Lu Y; Sun H; Wang H; Wen X; Xu D; Yang J; Zhang J; Zhao H; Zhou J; Zhu L; Bai L; Cao K; Chen M; Chen M; Dai G; Ding W; Dong W; Fang Q; Fang W; Fu X; Gao W; Gao R; Ge J; Ge Z; Gu F; Guo Y; Han H; Hu D; Huang W; Huang L; Huang C; Huang D; Huo Y; Jin W; Ke Y; Lei H; Li X; Li Y; Li D; Li G; Li X; Li Z; Liang Y; Liao Y; Liu G; Ma A; Ma C; Ma D; Ma Y; Shen L; Sun J; Sun C; Sun Y; Tang Q; Wan Z; Wang H; Wang J; Wang S; Wang D; Wang G; Wang J; Wu Y; Wu P; Wu S; Wu X; Wu Z; Yang T; Yang X; Yang Y; Yang Z; Ye P; Yu B; Yuan F; Zhang S; Zhang Y; Zhang R; Zhang Y; Zhang Y; Zhao S; Zhou X, 2015, 'Guidelines for the prevention, diagnosis, and treatment of infective endocarditis in adults', European Heart Journal, Supplement, 17, pp. C1 - C16, http://dx.doi.org/10.1093/eurheartj/suv031

Xiang D; Shigdar S; Qiao G; Zhou SF; Li Y; Wei MQ; Qiao L; Al Shamaileh H; Zhu Y; Zheng C; Pu C; Duan W, 2015, 'Aptamer-mediated cancer gene therapy', Current Gene Therapy, 15, pp. 109 - 119, http://dx.doi.org/10.2174/1566523214666141224095105

Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Al Shamaileh H; Yin W; Zhou SF; Zhao X; Duan W, 2015, 'Cancer stem cell targeted therapy: Progress amid controversies', Oncotarget, 6, pp. 44191 - 44206, http://dx.doi.org/10.18632/oncotarget.6176

Xiang D; Shigdar S; Qiao G; Wang T; Kouzani AZ; Zhou SF; Kong L; Li Y; Pu C; Duan W, 2015, 'Nucleic acid aptamer-guided cancer therapeutics and diagnostics: The next generation of cancer medicine', Theranostics, 5, pp. 23 - 42, http://dx.doi.org/10.7150/thno.10202

Xiang D; Zheng C; Zhou SF; Qiao S; Tran PHL; Pu C; Li Y; Kong L; Kouzani AZ; Lin J; Liu K; Li L; Shigdar S; Duan W, 2015, 'Superior performance of aptamer in tumor penetration over antibody: Implication of aptamer-based theranostics in solid tumors', Theranostics, 5, pp. 1083 - 1097, http://dx.doi.org/10.7150/thno.11711

Lei C; Wasinger V; Graham P; Hao J; Ni J; Beretov J; Bucci J; Cozzi P; Kearsley J; Li Y, 2014, 'THE USE OF LABEL-FREE LC-MS/MS APPROACH TO IDENTIFY SIGNALING PATHWAYS ASSOCIATED WITH PROSTATE CANCER RADIORESISTANCE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, pp. 130 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Shigdar S; O'Connor M; Lin J; Wang T; Xiang D; Duan W; Li Y; Bhattacharya S; Pu C; Kong L; Wei MQ; Zhu Y; Zhou S, 2014, 'Inflammation and cancer stem cells', Cancer Letters, 345, pp. 271 - 278, http://dx.doi.org/10.1016/j.canlet.2013.07.031

Shigdar S; Li Y; Bhattacharya S; O'Connor M; Pu C; Lin J; Wang T; Xiang D; Kong L; Wei MQ; Zhu Y; Zhou S; Duan W, 2014, 'Inflammation and cancer stem cells', Cancer Letters, 345, pp. 271 - 278, http://dx.doi.org/10.1016/j.canlet.2013.07.031

O'Connor ML; Xiang D; Shigdar S; Macdonald J; Li Y; Wang T; Pu C; Wang Z; Qiao L; Duan W, 2014, 'Cancer stem cells: A contentious hypothesis now moving forward', Cancer Letters, 344, pp. 180 - 187, http://dx.doi.org/10.1016/j.canlet.2013.11.012

Ni J; Cozzi P; Hao J; Duan W; Graham P; Kearsley J; Li Y, 2014, 'Cancer stem cells in prostate cancer chemoresistance', Current Cancer Drug Targets, 14, pp. 225 - 240, http://dx.doi.org/10.2174/1568009614666140328152459

Chang L; Graham PH; Hao J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy', Cancer and Metastasis Reviews, 33, pp. 469 - 496, http://dx.doi.org/10.1007/s10555-014-9493-5

Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways', Cell Death and Disease, 5, http://dx.doi.org/10.1038/cddis.2014.415

Chang L; Graham PH; Hao J; Jie N; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 34, pp. S50 - S50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000341276000182&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Beretov J; Wasinger VC; Graham PH; Millar EK; Kearsley JH; Li Y, 2014, 'Proteomics for breast cancer urine biomarkers', , 63, pp. 123 - 167, http://dx.doi.org/10.1016/B978-0-12-800094-6.00004-2

Beretov J; Wasinger VC; Schwartz P; Graham PH; Li Y, 2014, 'A Standardized and Reproducible Urine Preparation Protocol for Cancer Biomarkers Discovery', Biomarkers in Cancer, 6, pp. bic.s17991 - bic.s17991, http://dx.doi.org/10.4137/bic.s17991

Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y, 2014, 'CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance', The Prostate, 74, pp. 602 - 617, http://dx.doi.org/10.1002/pros.22775

Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y, 2013, 'The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression', Cancer and Metastasis Reviews, 32, pp. 535 - 551, http://dx.doi.org/10.1007/s10555-013-9423-y

Chang L; Graham P; Hao J; Ni J; Bucci J; Cozzi P; Kearseley J; Li Y, 2013, 'PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.', MOLECULAR CANCER THERAPEUTICS, 12, http://dx.doi.org/10.1158/1535-7163.TARG-13-A283

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2013, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway', International Journal of Biochemistry and Cell Biology, 45, pp. 2736 - 2748, http://dx.doi.org/10.1016/j.biocel.2013.09.008

Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2013, 'Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance', Cell Death and Disease, 4, http://dx.doi.org/10.1038/cddis.2013.407

Xiao W; Graham PH; Hao J; Chang L; Ni J; Power CA; Dong Q; Kearsley JH; Li Y, 2013, 'Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0074253

You J; Willcox MD; Madigan MC; Wasinger V; Schiller B; Walsh BJ; Graham PH; Kearsley JH; Li Y, 2013, 'Tear Fluid Protein Biomarkers', , 62, pp. 151 - 196, http://dx.doi.org/10.1016/B978-0-12-800096-0.00004-4

O'Connor ML; Xiang D; Shigdar S; Macdonald J; Wang T; Duan W; Li Y; Pu C; Wang Z; Qiao L, 2013, 'Cancer stem cells: A contentious hypothesis now moving forward', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2013.11.012

Shigdar S; O'Connor M; Lin J; Wang T; Xiang D; Duan W; Li Y; Bhattacharya S; Pu C; Kong L; Wei MQ; Zhu Y; Zhou S, 2013, 'Inflammation and cancer stem cells', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2013.07.031

Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kersley JH; Li Y, 2013, 'Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro', Cancer Letters, 1, pp. 17 - 26

Shigdar S; Qiao L; Zhou S; Xiang D; Wang T; Li Y; Lim L; Kong L; Li LH; Duan W, 2013, 'RNA aptamers targeting cancer stem cell marker CD133', Cancer Letters, 330, pp. 84 - 95, http://dx.doi.org/10.1016/j.canlet.2012.11.032

Hao J; Ni J; Cozzi PJ; Graham PH; Bucci J; Kearsley J; Li Y, 2013, 'The CD44 Isoforms in Prostate Cancer Metastasis and progression', World Journal of Cancer Research, 1, pp. 3 - 14, http://dx.doi.org/10.1166/wjcr.2013.1009

Shigdar S; Qian C; Lv LX; Pu C; Li Y; Li LH; Marappan M; Lin J; Wang L; Duan W, 2013, 'The Use of Sensitive Chemical Antibodies for Diagnosis:Detection of Low Levels of Epcam in Breast Cancer', PLoS One, 8, pp. Article numbere57613, http://dx.doi.org/10.1371/journal.pone.0057613

Shigdar S; Lin J; Li Y; Yang C; Wei M; Zhu Y; Liu H; Duan W, 2012, 'Cancer stem cell targeting: The next generation of cancer therapy and molecular imaging', Therapeutic Delivery, 3, pp. 227 - 244, http://dx.doi.org/10.4155/tde.11.148

Xiao W; Graham PH; Power C; Hao J; Kearsley J; Li Y, 2012, 'CD44 is a biomarker associated with human prostate cancer radiation sensitivity', Clinical and Experimental Metastasis, 29, pp. 1 - 9, http://dx.doi.org/10.1007/s10585-011-9423-7

Hao J; Madigan MC; Khatri A; Power C; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley J; Li Y, 2012, 'In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147', PLoS One, 7, pp. 1 - 14, http://dx.doi.org/10.1371/journal.pone.0040716

Ni J; Cozzi PJ; Duan W; Shigdar S; Graham PH; Kearsley J; Li Y, 2012, 'Role of the EpCAM (CD326) in prostate cancer metastasis and progression.', Cancer and Metastasis Reviews, 31, pp. 779 - 791, http://dx.doi.org/10.1007/s10555-012-9389-1

Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins A; Kearsley J; Li Y, 2011, 'Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model.', PLoS One, 6(9), pp. 1 - 13, http://dx.doi.org/10.1371/journal.pone.0024405

Wang L; Chen H; Liu F; Madigan MC; Power C; Hao J; Patterson K; Pourgholami MH; O Brien P; Perkins A; Li Y, 2011, 'Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer', Cancer Letters, 300, pp. 122 - 133, http://dx.doi.org/10.1016/j.canlet.2010.09.013

Li Y; Cozzi PJ, 2010, 'ChemInform Abstract: Angiogenesis as a Strategic Target for Prostate Cancer Therapy', ChemInform, 41, http://dx.doi.org/10.1002/chin.201020259

Li Y; Cozzi PJ; Russell PJ, 2010, 'ChemInform Abstract: Promising Tumor‐Associated Antigens for Future Prostate Cancer Therapy', ChemInform, 41, http://dx.doi.org/10.1002/chin.201020260

Li Y, 2010, 'The detection of tear biomarkers for future prostate cancer diagnosis', Open Biomarkers Journal, 3, pp. 26 - 29, http://dx.doi.org/10.2174/1875318301003010026

Li Y; Cozzi PJ, 2010, 'Angiogenesis as a strategic target for prostate cancer therapy', Medicinal Research Reviews, 30, pp. 23 - 66, http://dx.doi.org/10.1002/med.20161

Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y, 2010, 'CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer', Current Cancer Drug Targets, 10, pp. 287 - 306

Hao JL; Chen H; Madigan MC; Cozzi PJ; Beretov J; Xiao W; Delprado W; Russell PJ; Li Y, 2010, 'Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.', British Journal of Cancer, 103, pp. 1008 - 1018, http://dx.doi.org/10.1038/sj.bjc.6605839

Chen H; Wang L; Beretov J; Hao J; Xiao W; Li Y, 2010, 'Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression', Clinical and Experimental Metastasis, 27, pp. 557 - 569, http://dx.doi.org/10.1007/s10585-010-9345-9

Chen H; Wang L; Beretov J; Xiao W; Li YH; Hao J, 2010, 'Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression', Clinical and Experimental Metastasis, 27, pp. 557 - 569, http://dx.doi.org/10.1007/s10585-010-9345-9

Back to profile page